Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, the company received the “Drug Registration Certificate” for agomelatine tablets approved and issued by the State Drug Administration. Agomelatine has a dual mechanism of action as a melatonin receptor agonist (MT1/MT2) and a 5-HT2C receptor antagonist, and is clinically used to treat depression in adults.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.